Octreotide

Therapeutic Group

Pituitary And Hypothalamic Hormones And Analogues

Indication Dosage

Symptoms Associated With Carcinoid Tumours With Features Of Carcinoid Syndrome, Vipomas, and Glucagonomas: 

By Sc Inj: 

  • Adult: Initially 50 Mcg 1-2 Times A Day, Adjusted According To Response; Increased To 200 Mcg 3 Times A Day, Higher Doses May Be Required Exceptionally; Maintenance Doses Are Variable; In Carcinoid Tumours, Discontinue After 1 Week If No Effect, If Rapid Response Required, Initial Dose May Be Given By IV Injection (with Ecg Monitoring And After Dilution) 

Acromegaly, Short-term Treatment Before Pituitary Surgery Or Long-term Treatment In Those Inadequately Controlled By Other Treatment Or Until Radiotherapy Becomes Fully Effective: 

By Sc Inj: 

  • Adult: 100-200 Mcg 3 Times A Day, Discontinue If No Improvement Within 3 Months 

Prevention Of Complications Following Pancreatic Surgery: 

By Sc Inj: 

  • Adult: (consult Product Literature) 

Test Dose Before Use Of Depot Preparation: 

By Sc Inj: 

  • Adult: Test Dose 50-100 Mcg For 1 Dose, Test Dose Should Be Given If Subcutaneous Octreotide Not Previously Given 

Acromegaly, Neuroendocrine (particularly Carcinoid) Tumour Adequately Controlled By Subcutaneous Octreotide: 

By Deep IM Inj Using Depot Inj: 

  • Adult: Initially 20 Mg Lar Injection Every 4 Weeks For 3 Months Then Adjusted According To Response, Increased If Necessary Up To 30 Mg Lar Injection Every 4 Weeks, To Be Administered Into The Gluteal Muscle, For Acromegaly, Start Depot 1 Day After The Last Dose Of Subcutaneous Octreotide, For Neuroendocrine Tumours, Continue Subcutaneous Octreotide For 2 Weeks After First Dose Of Depot Octreotide 

Advanced Neuroendocrine Tumours Of The Mid Gut, Or Tumours Of Unknown Primary Origin Where Non-mid Gut Sites Of Origin Have Been Excluded: 

By Deep IM Inj Using Depot Inj: 

  • Adult: 30 Mg Lar Injection Every 4 Weeks 

Reduce Intestinal Secretions In Palliative Care and reduce Vomiting Due To Bowel Obstruction In Palliative Care: By Continuous Sc Infusion: 

  • Adult: 0.25-0.5 Mg/24 Hours (max. Per Dose0.75 Mg/24 Hours), Occasionally Doses Higher Than The Maximum Are Sometimes Required

Content

  • Inj 0.05mg /0.1mg: Per 1 ml Amp: Octreotide (as Acetate) 0.05mg /0.1mg; Solution.
  • Inj: Octreotide (as Acetate) 20mg; Micro-spheres For Susp; In Vials Plus 2 Amp Of Diluent, Syringe And 2 N

Pregnancy

Consult with Doctor Or Caution Advised

Stability

  • Somatostatin Analogue

Contra Indications

  • Pregnancy, Lactation.

Precautions

  • Pregnancy, Lactation.

Lactation

  • Consult with Doctor Or Caution Advised

Side Effects

  • Alopecia
  • Arrhythmias
  • Biliary Colic (associated With Abrupt Withdrawal Of Subcutaneous Octreotide)
  • Bradycardia
  • Dehydration
  • Dizziness
  • Dyspnea
  • Headache
  • Hepatitis
  • Pancreatitis (associated With Abrupt Withdrawal Of Subcutaneous Octreotide)
  • Rash